Communications between Gilead and USTR regarding Malaysia compulsory license on HCV patents, 2017 to May 2018

The attached document is a 78 page PDF file obtained from USTR under the Freedom of Information Act (copy here), regarding communications between Gilead and USTR, over Malaysia’s decision to grant a compulsory license on patents for HCV treatments. This… Continue Reading

Roadblocks ahead on the WHO Roadmap on Access to Medicines and Vaccines?

By Katy Athersuch [1] and Thiru Balasubramaniam In May 2018, the World Health Assembly (WHA) adopted decision WHA71(8) requesting WHO’s Director-General to “elaborate a roadmap, in consultation with Member States, outlining the programming of WHO’s work on access to medicines… Continue Reading

Comments on NIH Prospective Exclusive License on Diabetes Treatments

Update. NIH sent us a 147 word response on November 23, 2018: NIH to KEI regarding Ovensa 23 NOV 2018. The brief reply states that “Prior to posting notices of a proposed grant of exclusive commercialization licenses, the NIH determines… Continue Reading

WTO TRIPS Council: South Africa asks WTO members to share best practices to address excessive prices

UPDATE: In November 2018, South Africa notified the WTO Secretariat that Brazil and India requested to co-sponsor this submission on Promoting Public Health Through Competition Law and Policy. On 29 October 2018, the World Trade Organization (WTO) published a submission… Continue Reading

WHO EURO RC68: Oral statement of Knowledge Ecology International on the WHO Roadmap on Access to Medicines and Vaccines

On Thursday, 20 September 2018, Knowledge Ecology International (KEI) delivered the following statement in Rome during discussions at the WHO Regional Committee for Europe on the WHO Roadmap on Access to Medicines and Vaccines. Oral statement of Knowledge Ecology International… Continue Reading